Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 2/20 | 0.97 |
| ▸ | GLA | P06280 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PON1 | P27169 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vadimezan SCHEMBL29363732 | 0.99 | STING1 (1.00) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| Vadimezan SCHEMBL111183 | 0.99 | STING1 (1.00) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| Vadimezan SCHEMBL29356696 | 0.99 | STING1 (1.00) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| Vadimezan SCHEMBL4282930 | 0.97 | STING1 (0.97) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL13025119 | 0.88 | GLA (0.81) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL8280464 | 0.87 | GLA (0.79) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL19209663 | 0.87 | GLA (0.79) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL20762991 | 0.87 | STING1 (0.79) | STING1GLASMN1; SMN2KDM4ETDP1 | |
| SCHEMBL20845573 | 0.87 | GLA (0.79) | STING1GLASMN1; SMN2KDM4EMCL1 | |
| SCHEMBL9381286 | 0.86 | STING1 (0.78) | STING1GLASMN1; SMN2KDM4EMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009156459-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | claimed |
| CN-101878206-A | Crystalline forms of (5, 6-dimethyl-9-oxo-9H-xanthen-4-yl) acetic acid sodium salt | ANTISOMA RES LTD | 2010-11-03 | — | — | CN | disclosed |
| CN-101878206-A | Crystalline forms of (5, 6-dimethyl-9-oxo-9H-xanthen-4-yl) acetic acid sodium salt | ANTISOMA RES LTD | 2010-11-03 | — | — | CN | disclosed |
| WO-2009156459-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |